These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27563077)

  • 41. Carotid intima-media thickness in children with familial hypercholesterolemia.
    Kusters DM; Wiegman A; Kastelein JJ; Hutten BA
    Circ Res; 2014 Jan; 114(2):307-10. PubMed ID: 24192652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract]   [Full Text] [Related]  

  • 43. [New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors].
    Ribeiro L; Kohn IJ
    Arq Bras Cardiol; 1990 Mar; 54(3):177-8. PubMed ID: 2288502
    [No Abstract]   [Full Text] [Related]  

  • 44. Homozygous familial hypercholesterolaemia and treatment by LDL apheresis.
    King RI; Scott RS; Florkowski CM; Laurie AD; Reid N; George PM
    N Z Med J; 2010 Jul; 123(1319):79-82. PubMed ID: 20717180
    [No Abstract]   [Full Text] [Related]  

  • 45. Association of high total cholesterol with coronary heart disease mortality differs among subject populations--familial hypercholesterolemia as a key concept.
    Okuyama H; Ichikawa Y; Sun Y; Hamazaki T; Lands WE
    World Rev Nutr Diet; 2007; 96():19-36. PubMed ID: 17167278
    [No Abstract]   [Full Text] [Related]  

  • 46. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decision to reject screening for familial hypercholesterolaemia is flawed.
    Wald DS; Martin AC
    Arch Dis Child; 2021 Jun; 106(6):525-526. PubMed ID: 32601084
    [No Abstract]   [Full Text] [Related]  

  • 48. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Paradigm shift with the new American guidelines for lipid-lowering therapy].
    Hjemdahl P; Andersén-Karlsson E
    Lakartidningen; 2014 Apr 2-8; 111(14):596-7. PubMed ID: 24779174
    [No Abstract]   [Full Text] [Related]  

  • 50. [Is statin treatment for children safe and effective?].
    Marchetti F; Cannioto Z
    Recenti Prog Med; 2008 Dec; 99(12):599-601. PubMed ID: 19388217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New EAS Consensus Statement on FH: improving the care of FH patients.
    Stock J
    Atherosclerosis; 2013 Nov; 231(1):69-71. PubMed ID: 24125413
    [No Abstract]   [Full Text] [Related]  

  • 52. [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document].
    Mata P; Alonso R; Ruiz A; Gonzalez-Juanatey JR; Badimón L; Díaz-Díaz JL; Muñoz MT; Muñiz O; Galve E; Irigoyen L; Fuentes-Jiménez F; Dalmau J; Pérez-Jiménez F
    Semergen; 2015; 41(1):24-33. PubMed ID: 25042971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 54. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Hopkins PN; Toth PP; Ballantyne CM; Rader DJ;
    J Clin Lipidol; 2011 Jun; 5(3 Suppl):S9-17. PubMed ID: 21600530
    [No Abstract]   [Full Text] [Related]  

  • 55. Dose-dependent effect of hydroxymethylglutaryl-coenzyme A reductase inhibitor on serum cholesterol with limited dietary restrictions: a case study.
    Okada S; Ichiki K; Tanokuchi S; Ota Z
    J Int Med Res; 1993; 21(2):105-11. PubMed ID: 8243790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 57. Updated National Cholesterol Education Program III guidelines.
    Aronow WS
    J Am Med Dir Assoc; 2005; 6(2):160-1. PubMed ID: 15871897
    [No Abstract]   [Full Text] [Related]  

  • 58. NICE guidance on familial hypercholesterolaemia: all sugar and spice?
    Watts GF; Hamilton-Craig I; Sullivan DR
    Heart Lung Circ; 2009 Jun; 18(3):181-3. PubMed ID: 19119070
    [No Abstract]   [Full Text] [Related]  

  • 59. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 60. Pleiotropic effects of statins in the prevention of coronary heart disease--potential side effects.
    Okuyama H; Ichikawa Y; Sun Y; Hamazaki T; Lands WE
    World Rev Nutr Diet; 2007; 96():55-66. PubMed ID: 17167280
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.